ClinicalTrials.gg
CompletedNCT00547521Updated Mar 23, 2015Results posted

Phase IIIB Subcutaneous Abatacept Monotherapy Study

A Phase 3 interventional study of abatacept and Methotrexate (MTX) in Rheumatoid Arthritis (RA), sponsored by Bristol-Myers Squibb. Completed at 22 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-03-23.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
119
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 63 studies testing abatacept in Arthritis, Rheumatoid — 3 open to participants now, 4 under way, 3 of them phase 3. Abatacept · Arthritis, Rheumatoid.

Enrollment
31st of 63
119 · median 119
Started
2007
with 5 others
Phase 3
26 of 63
2 open now
Registered
18th of 63
by date
Lead sponsor
33 of 63
Bristol-Myers Squibb

Among the 63 studies testing abatacept in Arthritis, Rheumatoid, this one is the 31st largest by enrollment, is one of 6 that started in 2007, is one of 26 in phase 3, and was the 18th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

3 of the 63 studies testing abatacept in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About abatacept

Abatacept: first FDA approval 2005 (ORENCIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies testing abatacept in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

To evaluate safety and immunogenicity of abatacept when used with or without methotrexate in the absence of an IV loading dose of abatacept

03

Conditions studied

  • Rheumatoid Arthritis (RA)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of Rheumatoid Arthritis
  • Subjects Global Disease Assessment of greater than equal to 20 mm on a visual analog scale
  • Discontinue all Biologics and Disease-modifying antirheumatic drugs (DMARDS) except for methotrexate

Exclusion criteria

Exclusion Criteria:

  • Received treatment with rituximab
  • Subjects who have received treatment with immunoadsorbtion columns (such as Prosorba columns), mycophenolate mofetil (Cellcept®), cyclosporine A or other calcineurin inhibitors, or D-Penicillamine
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
119 participants (actual)

Study arms

  • Experimental
    Subcutaneous (SC) Abatacept + Methotrexate (MTX) Cohort

    In the ST period, participants were administered a dose of 125 mg abatacept SC, once weekly, for 4 months. Participants were also administered a stable MTX dose of greater than or equal to 10 mg once weekly for at least 4 weeks prior to first injection of SC abatacept.

    Drug: abatacept · Drug: Methotrexate (MTX)

  • Experimental
    SC Abatacept Monotherapy Cohort

    In the ST period, participants were administered a dose of 125 mg abatacept SC, once weekly, for 4 months. Participants did not receive MTX at screening i.e., MTX naive, or discontinued MTX due to lack of efficacy or tolerability at least 4 weeks prior to first injection of SC abatacept.

    Drug: abatacept

Interventions

  • solution, subcutaneous injection, 125 mg/kg, weekly, 106 days in short term; long term is open

    Also known as: BMS-188667, Orencia®

  • Participants who were currently receiving methotrexate at a stable dose ≥ 10 mg for at least 4 weeks

06

What researchers measure

Primary outcomes

  1. Number of Participants With Anti-abatacept or Anti-CTLA4-T Responses (Enzyme-linked Immunosorbent Assay [ELISA] Method) at Day 113 of the ST Study

    ELISA is a validated, sensitive assay technique used to analyze presence of abatacept-specific antibodies in serum. For anti-abatacept antibody ELISA, a sample was considered seropositive if it had a titer of 400 or greater and if immunodepletion was observed. The responses that were negative in initial screen were reported as seronegative with a value of \< 400. A sample was considered positive in CTLA4-T antibody ELISA if it had a titer of 25 or greater and if immunodepletion was observed. The responses that were negative in initial screen were reported as seronegative with a value of \< 25.

    Time frame: Day 113

  2. Number of Participants With Anti-abatacept or Anti-CTLA4-T Responses (ELISA Method) Over Time During the ST Study

    ELISA is a validated, sensitive assay technique used to analyze presence of abatacept-specific antibodies in serum. For anti-abatacept antibody ELISA, a sample was considered seropositive if it had a titer of 400 or greater and if immunodepletion was observed. The responses that were negative in initial screen were reported as seronegative with a value of \< 400. A sample was considered positive in CTLA4-T antibody ELISA if it had a titer of 25 or greater and if immunodepletion was observed. The responses that were negative in initial screen were reported as seronegative with a value of \< 25.

    Time frame: Day 15, 29, 43, 57, 85,113 and 28, 56, and 85 days post last dose.

  3. Number of Participants With Positive Anti-abatacept Responses to Abatacept (Meso-Scale Discovery [MSD] Electrochemiluminescence [ECL] Assay Method) Over Time During the ST Study

    The ECL (MSD) assay method is a validated, sensitive assay technique used to analyze presence of abatacept-specific antibodies in serum. It is more sensitive and has a higher drug tolerance than ELISA method. For the anti-abatacept antibody ECL (MSD) assay, a sample was considered seropositive if it had a titer of 10 or greater and if immunodepletion was observed with abatacept, or abatacept and CTLA4-T. Those responses that were not positive in the initial screen or were not confirmed to be positive based on immunodepletion were reported as seronegative and were assigned a value of \< 10.

    Time frame: Day 15, 29, 43, 57, 85,113 and 28, 56 and 85 days post last dose.

  4. Immunogenicity in MTX Naive and MTX-previous Users in Cohort 1 at Day 113 of the ST Study (for ELISA Results)

    ELISA is a validated, sensitive assay technique used to analyze presence of abatacept-specific antibodies in serum. For anti-abatacept antibody ELISA, a sample was considered seropositive if it had a titer of 400 or greater and if immunodepletion was observed. The responses that were negative in initial screen were reported as seronegative with a value of \< 400. A sample was considered positive in CTLA4-T antibody ELISA if it had a titer of 25 or greater and if immunodepletion was observed. The responses that were negative in initial screen were reported as seronegative with a value of \< 25.

    Time frame: Day 113.

  5. Immunogenicity in MTX Naive and MTX-previous Users in Cohort 1 at Day 113 of the ST Study (for MSD Results)

    The ECL (MSD) assay method is a validated, sensitive assay technique used to analyze presence of abatacept-specific antibodies in serum. It is more sensitive and has a higher drug tolerance than the ELISA method. For anti-abatacept antibody ECL (MSD) assay, a sample was considered seropositive if it had a titer of 10 or greater and if immunodepletion was observed with abatacept, or abatacept and CTLA4-T. Those responses that were not positive in the initial screen or were not confirmed to be positive based on immunodepletion were reported as seronegative and were assigned a value of \< 10.

    Time frame: Day 113.

  6. Cross Tabulations of the Number of Participants With Positive and Negative Immunogenicity Status at Baseline and Each Visit During the ST Study (for ELISA Results)

    ELISA is a validated, sensitive assay technique used to analyze presence of abatacept-specific antibodies in serum. For anti-abatacept antibody ELISA, a sample was considered seropositive if it had a titer of 400 or greater and if immunodepletion was observed. The responses that were negative in initial screen were reported as seronegative with a value of \< 400. A sample was considered positive in CTLA4-T antibody ELISA if it had a titer of 25 or greater and if immunodepletion was observed. The responses that were negative in initial screen were reported as seronegative with a value of \< 25.

    Time frame: Baseline and on day 15, 29, 43, 57, 85 and 113

  7. Cross Tabulations of the Number of Participants With Positive and Negative Immunogenicity Status at Baseline and Each Visit During the ST Study (for MSD Results)

    The ECL (MSD) assay method is a validated, sensitive assay technique used to analyze presence of abatacept-specific antibodies in serum . It is more sensitive and has a higher drug tolerance than the ELISA method. For anti-abatacept antibody ECL(MSD) assay, a sample was considered seropositive if it had a titer of 10 or greater and if immunodepletion was observed with abatacept, or abatacept and CTLA4-T. Those responses that were not positive in the initial screen or were not confirmed to be positive based on immunodepletion were reported as seronegative and were assigned a value of \< 10.

    Time frame: Baseline and day 15, 29, 43, 57, 85 and 113.

Secondary outcomes

  1. Change From Baseline in DAS28-CRP Score at End of 4-month (Day 113) of the ST Study

    DAS28-CRP is a continuous variable which is a composite of 4 variables: the number of tender joint out of 28, the number of swollen joint out of 28, C-reactive protein (CRP) in milligrams/Liter (mg/L) and subject assessment of disease activity measure on a VAS of 100mm. DAS 28 = 0.56 \* sqrt(tender28) + 0.28 \* sqrt(swollen28) + 0.36 \* ln(CRP+1) + 0.014 \* VAS + 0.96.

    Time frame: Baseline and Month 4 (Day113).

  2. Number of Participants With Clinically Meaningful Improvement at End of 4-month (Day 113) of the ST Study

    A clinically meaningful improvement is defined as a greater than or equal to 1.2 reduction in DAS28-CRP score from baseline.

    Time frame: Day 113.

  3. Change From Baseline in Physical Functioning (HAQ-DI) at End of the 4-month Treatment Period (Day 113) of the ST Study

    HAQ-DI takes into account participant's use of aids or devices or assistance in scoring algorithm for a disability category. The questionnaire includes 20 questions assessing physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The questions are evaluated on a 4-point scale: 0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty and 3 = unable to do. Higher scores indicate greater dysfunction. The score is calculated by summing worst scores in each domain and dividing by the number of domains answered.

    Time frame: Baseline and Month 4 (Day 113).

  4. Change From Baseline in All HAQ-DI Components at End of the 4-month Treatment Period (Day 113) of the ST Study

    HAQ-DI takes into account participant's use of aids or devices or assistance in scoring algorithm for a disability category. The questionnaire includes 20 questions assessing physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The questions are evaluated on a 4-point scale: 0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty and 3 = unable to do. Higher scores indicate greater dysfunction. The score is calculated by summing worst scores in each domain and dividing by the number of domains answered.

    Time frame: Baseline and Month 4 (Day113).

  5. Cross Tabulations of Number of Participants With Positive and Negative Status for RF at Day 113 With Baseline, in the ST Study

    RF is an autoantibody that is usually present in the serum of people with rheumatoid arthritis. The cut-point value for seroconversion was 15 IU/mL (\>= 15 IU/mL resulted in a positive result). Cross-tabulation of frequency of seroconversion of RF at Day 113 with baseline, in the ST period, was provided.

    Time frame: Baseline and Day 113.

  6. Number of Participants Who Died, Experienced SAEs, Experienced AEs or Who Discontinued Due to AEs During the ST Study

    AEs: any new untoward medical occurrences/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose. Participants who discontinued the study due to any AEs or SAEs were recorded.

    Time frame: Continuously through ST period (upto Day 113). Includes the data from start of study drug therapy up to 56 days after the last dose (Day 113) or start of the long-term period whichever occurred first.

  7. Number of Participants Who Experienced Drug-related SAEs and Drug-related AEs During the ST Study

    Drug-related AEs are those events with a relationship to the study therapy of certain; probable; possible; or missing. Drug-related SAEs are those events with any relationship to the study therapy.

    Time frame: Continuously through ST period (upto Day 113). Includes the data from start of study drug therapy up to 56 days after the last dose (Day 113) or start of the long-term period whichever occurred first.

  8. Number of Participants With AEs of Special Interest During the ST Study

    An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition (even if not caused by the study drug). For this study, AEs of particular importance were associated with the use of immunomodulatory agents: infections, autoimmune disorders, malignancies, and injection reaction AEs (systemic AEs occurring within 24 hours of SC injection and local injection site reactions) were recorded.

    Time frame: Continuously through ST period (up to Day 113). Includes the data from start of study drug therapy up to 56 days after the last dose (Day 113) or start of the long-term period whichever occurred first.

  9. Number of Participants With Marked Abnormalities (MAs) in Hematology During the ST Study: Hemoglobin, Hematocrit, Platelet Count, Erythrocytes and Leukocytes

    MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following hematology MA definitions specify the criteria for the data presented. Hemoglobin: \>3 g/dL decrease from pre-treatment (pre Rx); hematocrit: \<0.75 \* pre-Rx value; platelet count: \<0.67 \* (LLN -lower limit of normal) (or, if pre-Rx value \<LLN, then \<0.5 \* pre-Rx value and \<100,000/mm\^3); leukocytes: \<0.75 \* LLN or \>1.25 \* ULN (or, if pre-Rx value \<LLN, then \<0.8 \* pre-Rx or \>(ULN -upper limit of normal) ; erythrocytes: \<0.75 \* pre Rx.

    Time frame: Continuously from start of ST period up to 56 days post the last dose in the short-term period or start of the long-term period, whichever occurred first.

  10. Number of Participants With MAs in Hematology During the ST Study: Neutrophils + Bands (Absolute), Lymphocytes (Absolute), Monocytes (Absolute), Basophils (Absolute) and Eosinophils (Absolute)

    MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following hematology MA definitions specify the criteria for the data presented. Neutrophils + bands (absolute): \<1.00 \* 10\^3cells/microlitre (uL); lymphocytes (absolute): \<0.75 \* 10\^3 cells/uL or \>7.50 \* 10\^3 cells/uL; monocytes (absolute): \>2.00 \* 10\^3 cells/uL; basophils (absolute): \>0.40 \* 10\^3 cells/uL; eosinophils (absolute): \>0.75 \* 10\^3 cells/uL.

    Time frame: Continuously from start of ST period up to 56 days post the last dose in the short-term period or start of the long-term period, whichever occurred first.

  11. Number of Participants With MAs in Serum Chemistry During the ST Study: Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Bilirubin (Total), G-Glutamyl Transferase (G-GT) and Blood Urea Nitrogen (BUN)

    MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following serum chemistry MA definitions specify MA criteria. ALP: \>2.0 \* ULN (if pre-Rx \> ULN, then \>3 \* pre-Rx); AST, ALT: \> 3 \* ULN (if pre-Rx \> ULN, then \> 4 \* pre-Rx); bilirubin (total): \>2 \* ULN, or if pre Rx \> ULN then \>4 \* Pre Rx; BUN : \>2 \* pre Rx; GGT : \>2 \* ULN, or if pre Rx \> ULN then \>3 \* pre Rx.

    Time frame: Continuously from start of ST period up to 56 days post the last dose in the short-term period or start of the long-term period, whichever occurred first.

  12. Number of Participants With MAs in Serum Chemistry During the ST Study: Creatinine, Sodium (Serum), Potassium (Serum), Chloride (Serum), Calcium (Total) and Protein (Total)

    MAs= laboratory measurements marked as abnormal: creatinine: \>1.5 \* pre-Rx; sodium (serum):\<0.95 \* LLN or \>1.05 \* ULN (if pre-Rx \< LLN, then \<0.95 \* pre-Rx or \>1.05 \* ULN. If pre-Rx \> ULN, then \>0.95 \* pre-Rx or \< ULN); potassium (serum):\<0.9 \* LLN or \>1.1 \* ULN (if pre-Rx \< LLN, then \<0.9 \* pre-Rx or \> ULN; chloride (serum),protein (total):\<0.9 \* LLN or \>1.1 8 ULN (if pre-Rx \< LLN, then \<0.9 \* pre-Rx or \> ULN. If pre-Rx \> ULN, then \>1.1 \* pre-Rx or \< LLN); calcium (total): \<0.8 \* LLN or \>1.2 \* ULN (if pre-Rx \< LLN, then \<0.9 \* pre-Rx or \> ULN. If pre-Rx \> ULN, then \>0.75 \* pre-Rx or \< ULN).

    Time frame: Continuously from start of ST period up to 56 days post the last dose in the short-term period or start of the long-term period, whichever occurred first.

  13. Number of Participants With MAs in Serum Chemistry During the ST Study: Glucose (Fasting Serum), Albumin, Glucose (Serum), Phosphorous (Inorganic) and Uric Acid

    MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following serum chemistry MA definitions specify MA criteria. Glucose (fasting serum): \<0.8 \* LLN or \>1.5 ULN (if pre-Rx \<LLN, then \<2.0 \* pre-Rx or \>ULN; albumin: \<0.9 \* LLN (if pre-Rx \< LLN, then \<0.75 \* pre-Rx); uric acid: \>1.5 \* ULN (if pre-Rx \> ULN, then \>2.0 \* pre-Rx); phosphorous (inorganic):\<0.75 \* LLN or \>1.25 \* ULN (if pre-Rx \< ULN, then \<0.67 \* pre-Rx or \< ULN. If pre-Rx \> ULN, then \>1.33 \* re-Rx or \< LLN); glucose (serum): \<65 mg/dL or \>220 mg/dL.

    Time frame: Continuously from start of ST period up to 56 days post the last dose in the short-term period or start of the long-term period, whichever occurred first.

  14. Number of Participants With MAs in Urinalysis During the ST Study: Protein, Glucose, Blood, Leukocyte Esterase, Red Blood Cells (RBC) and White Blood Cells (WBC)

    MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following definitions specify the criteria for MAs in urinalysis: protein, glucose, blood, leukocyte esterase, RBC, WBC: \>= 2+ (or, if value \>= 4, or if pre-Rx value = 0 or 0.5, then \>= 2x or if pre-Rx value =1, then \>= 3, or if pre-Rx = 2 or 3, then \>= 4).

    Time frame: Continuously from start of ST period up to 56 days post the last dose in the short-term period or start of the long-term period, whichever occurred first.

  15. Number of Participants With Anti-nuclear Antibody (ANA) Category at Day 113 of the ST Study

    ANA status was categorized as negative or positive corresponding to the following dilutions: less than 1:160 and greater than equal to 1:160.

    Time frame: Day 113.

  16. Number of Participants With Anti-double Stranded DNA (dsDNA) Category at Day 113 of the ST Study

    Anti-dsDNA antibody status was categorized as negative or positive based upon assay-specific numeric cut-off values.

    Time frame: Day 113.

  17. Number of Participants With Clinically Meaningful Vital Signs During the ST Study

    Vital signs measurements (including seated blood pressure, heart rate and temperature) were recorded. The investigator used his/her clinical judgment to decide whether or not abnormalities in vital signs/physical examination were clinically meaningful.

    Time frame: At screening and on days 1,15,29,43, 57, 85 and 113.

  18. Minimum Plasma Concentration (Cmin) at Each Visit During the 4 Month Treatment Period of the ST Study

    Cmin serum abatacept concentration was obtained directly from the concentration-time data.

    Time frame: Days 1, 15, 29, 43, 57, 85 and 113.

  19. Number of Participants With Abatacept Induced Antibody Responses Over Time During the LTE Study (ECL Method) - All Treated Participants in LTE Study

    The Meso-Scale Discovery (MSD) electrochemiluminescence (ECL) assay method is a validated, sensitive assay technique used to analyze presence of abatacept-specific antibodies in serum. It is more sensitive and has a higher drug tolerance than ELISA method. For the anti-abatacept antibody ECL (MSD) assay, a sample was considered seropositive if it had a titer of 10 or greater and if immunodepletion was observed with abatacept, or abatacept and CTLA4-T. Those responses that were not positive in the initial screen or were not confirmed to be positive based on immunodepletion were reported as seronegative and were assigned a value of \< 10. Antibody responses included CTLA4 and possibly immune globulin (IG), IG and/or junction region.

    Time frame: Days 197, 281, 365, 449, 533, 617, 729, 813, 897, 981, 1093, 1177, 1261, 1345, 1457, 1541, 1625, 1709, 1821, 1989, days post dose: 28, 56, 85, 168

  20. Change From Baseline in DAS28-CRP Score in the LTE Study - All Treated Participants in LTE Study

    DAS28-CRP is a continuous variable which is a composite of 4 variables: the number of tender joints out of 28, the number of swollen joints out of 28, C-reactive protein (CRP) in milligrams/Liter (mg/L) and subject assessment of disease activity measure on a VAS of 100mm. DAS 28 = 0.56 \* sqrt(tender28) + 0.28 \* sqrt(swollen28) + 0.36 \* ln(CRP+1) + 0.014 \* VAS + 0.96. Baseline was Day 1 of the ST Study; Day 113 was the end of the ST Study.

    Time frame: Baseline, Day 113, Day 1345

  21. Number of Participants With Clinically Meaningful Improvement From Baseline in the LTE Study - All Treated Participants in LTE Study

    A clinically meaningful improvement is defined as a greater than or equal to 1.2 reduction in DAS28-CRP score from baseline. Baseline was Day 1 of the ST Study. Day 113 was the end of the ST Study.

    Time frame: Baseline, Day 113, Day 1345

  22. Number of Participants in DAS28-CRP Remission and Number of Participants With Low Disease Activity (LDA) in the LTE Study - All Treated Participants in the LTE

    DAS28-CRP remission was defined as DAS28-CRP less than 2.6 and LDA was defined as DAS28-CRP less than, equal to 3.2. End of ST Study was Day 113.

    Time frame: Day 113, Day 1345

  23. Change From Baseline in HAQ-DI in the LTE Study - All Treated Participants in LTE Study

    HAQ-DI takes into account participant's use of aids or devices or assistance in scoring algorithm for a disability category. The questionnaire includes 20 questions assessing physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The questions are evaluated on a 4-point scale: 0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty and 3 = unable to do. Higher scores indicate greater dysfunction. The score is calculated by summing worst scores in each domain and dividing by the number of domains answered. Baseline was Day 1 in the ST Study and Day 113 was the last day of the ST Study.

    Time frame: Baseline, Day 113, Day 1345

  24. Number of Participants With HAQ Responses in the LTE Study - All Treated Participants in the LTE STudy

    HAQ response was defined as an improvement of at least 0.3 units from baseline in the HAQ Disability Index (HAQ DI). Baseline was Day 1 of the ST Study and Day 113 was the last day of the ST Study.

    Time frame: Baseline, Day 113, Day 1345

  25. Number of Participants With Negative Status for RF up to 7 Days After Last Dose of Abatacept in the LTE Period - All Treated Participants in LTE Study

    RF is an autoantibody that is usually present in the serum of people with rheumatoid arthritis. The cut-point value for seroconversion was 15 IU/mL (\>= 15 IU/mL resulted in a positive result).

    Time frame: Continuously from start of LTE period up to 7 days post the last dose

  26. Change From Baseline in DAS28-CRP Score and Physical Function (HAQ-DI) Score in the LTE Study - Abatacept Monotherapy Subgroup

    Abatacept Monotherapy Subgroup consisted of participants who received SC abatacept and did not receive MTX in the ST and LTE Studies. DAS28-CRP: continuous variable which is a composite of 4 variables:number of tender joints out of 28, number of swollen joints out of 28, C-reactive protein (CRP) in mg/L and self assessment of disease activity measure on a VAS of 100mm. DAS 28 = 0.56 \* sqrt(tender28) + 0.28 \* sqrt(swollen28) + 0.36 \* ln(CRP+1) + 0.014 \* VAS + 0.96. HAQ-DI includes 20 questions assessing physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities on a 4-point scale: 0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty and 3 = unable to do. Higher scores indicate greater dysfunction. The score sums worst scores in each domain and divides by the number of domains answered. Baseline was Day 1 of Short Term Study. Day 113 was the last day of the Short Term Study.

    Time frame: Baseline, Day 113, Day 1345

  27. Number of Participants in DAS 28-CRP Remission and Low Disease Activity (LDA) in the LTE Study - Abatacept Monotherapy Subgroup

    Remission was defined as DAS 28-CRP \< 2.6 and LDA was defined as DAS 28-CRP \<= 3.2. End of ST Study was Day 113. Abatacept Monotherapy Subgroup was defined as those participants who received as at least 1 dose of abatacept and did not receive MTX in the ST and LTE Studies.

    Time frame: Day 113, Day 1345

  28. Number of Participants Who Died, Experienced Serious Adverse Events (SAEs), Adverse Events (AEs), or Discontinued Due to AEs and/or SAEs During the LTE Period - All Treated Participants in LTE Study

    AEs: any new untoward medical occurrences/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose. Drug-related AEs/SAEs are those events with a relationship to the study therapy of certain; probable; possible; or missing.

    Time frame: Continuously from start of LTE Study up to 56 days post the last dose

  29. Number of Participants With AEs of Special Interest During the LTE Study - All Treated Participants in LTE Study

    An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition (even if not caused by the study drug). For this study, AEs of particular importance were associated with the use of immunomodulatory agents: infections, autoimmune disorders, malignancies, and injection reaction AEs (systemic AEs occurring within 24 hours of SC injection and local injection site reactions) were recorded.

    Time frame: Continuously from start of LTE Study up to 56 days post the last dose

  30. Number of Participants With Marked Abnormalities (MAs) in Hematology During the LTE Period - All Treated Participants in LTE Study

    MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following hematology MA definitions specify the criteria for the data presented. Hemoglobin: \>3 g/dL decrease from pre-treatment (pre Rx); hematocrit: \<0.75 \* pre-Rx value; platelet count: \<0.67 \* (LLN -lower limit of normal) (or, if pre-Rx value \<LLN, then \<0.5 \* pre-Rx value and \<100,000/mm\^3); leukocytes: \<0.75 \* LLN or \>1.25 \* ULN (or, if pre-Rx value \<LLN, then \<0.8 \* pre-Rx or \>(ULN -upper limit of normal) ; erythrocytes: \<0.75 \* pre Rx. Neutrophils + bands (absolute): \<1.00 \* 10\^3cells/microlitre (uL); lymphocytes (absolute): \<0.75 \* 10\^3 cells/uL or \>7.50 \* 10\^3 cells/uL; monocytes (absolute): \>2.00 \* 10\^3 cells/uL; basophils (absolute): \>0.40 \* 10\^3 cells/uL; eosinophils (absolute): \>0.75 \* 10\^3 cells/uL.

    Time frame: Continuously from start of LTE Study up to 56 days post the last dose

  31. Number of Participants With MAs in Serum Chemistry (Liver and Kidney Function) During the LTE Period - All Treated Participants in LTE Study

    MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Bilirubin (Total), G-Glutamyl Transferase (G-GT), Blood Urea Nitrogen (BUN) and Creatinine MA criteria: ALP: \>2.0 \* ULN (if pre-Rx \> ULN, then \>3 \* pre-Rx); AST, ALT: \> 3 \* ULN (if pre-Rx \> ULN, then \> 4 \* pre-Rx); bilirubin (total): \>2 \* ULN, or if pre Rx \> ULN then \>4 \* Pre Rx; BUN : \>2 \* pre Rx; GGT : \>2 \* ULN, or if pre Rx \> ULN then \>3 \* pre Rx; creatinine: \>1.5 \* pre-Rx.

    Time frame: Continuously from start of LTE Study up to 56 days post the last dose

  32. Number of Participants With MAs in Serum Chemistry (Electrolytes, Glucose, Protein, and Metabolite) During the LTE Period - All Treated Participants in LTE Study

    Sodium (serum):\<0.95 \* LLN or \>1.05 \* ULN (if pre-Rx \< LLN, then \<0.95 \* pre-Rx or \>1.05 \* ULN. If pre-Rx \> ULN, then \>0.95 \* pre-Rx or \< ULN); potassium (serum):\<0.9 \* LLN or \>1.1 \* ULN (if pre-Rx \< LLN, then \<0.9 \* pre-Rx or \> ULN; chloride (serum),protein (total):\<0.9 \* LLN or \>1.1 8 ULN (if pre-Rx \< LLN, then \<0.9 \* pre-Rx or \> ULN. If pre-Rx \> ULN, then \>1.1 \* pre-Rx or \< LLN); calcium (total): \<0.8 \* LLN or \>1.2 \* ULN (if pre-Rx \< LLN, then \<0.9 \* pre-Rx or \> ULN. If pre-Rx \> ULN, then \>0.75 \* pre-Rx or \< ULN); phosphorous (inorganic):\<0.75 \* LLN or \>1.25 \* ULN (if pre-Rx \< ULN, then \<0.67 \* pre-Rx or \< ULN. If pre-Rx \> ULN, then \>1.33 \* re-Rx or \<LLN); glucose (serum): \<65 mg/dL or \>220 mg/dL; Glucose (fasting serum): \<0.8 \* LLN or \>1.5 ULN (if pre-Rx \<LLN, then \<2.0 \* pre-Rx or \>ULN; albumin: \<0.9 \* LLN (if pre-Rx \< LLN, then \<0.75 \* pre-Rx); uric acid: \>1.5 \* ULN (if pre-Rx \> ULN, then \>2.0 \* pre-Rx).

    Time frame: Continuously from start of LTE Study up to 56 days post the last dose

  33. Number of Participants With MAs in Urinalysis During the LTE Period: Protein, Glucose, Blood, Leukocyte Esterase, Red Blood Cells (RBC) and White Blood Cells (WBC) - All Treated Participants in LTE Study

    MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following definitions specify the criteria for MAs in urinalysis: protein, glucose, blood, leukocyte esterase, RBC, WBC: \>= 2+ (or, if value \>= 4, or if pre-Rx value = 0 or 0.5, then \>= 2x or if pre-Rx value =1, then \>= 3, or if pre-Rx = 2 or 3, then \>= 4).

    Time frame: Continuously from start of LTE Study up to 56 days post the last dose

07

Results

Posted Jan 24, 2011

Participant flow

Short term (ST) Study results (2 arms) were released in 2010. Final long term extension (LTE) results (1 arm with pooled data), up to 2014, are now included. During the LTE Study, 125 mg abatacept, was continued to be self-administered weekly and adjustments to RA medications including MTX were permitted at investigators discretion.

Short Term Study (4 Months)
Participant flow — Short Term Study (4 Months)
MilestoneSubcutaneous (SC) Abatacept + Methotrexate (MTX) CohortSC Abatacept Cohort
Started5149
Completed5045
Not completed14
Withdrew: Adverse event10
Withdrew: Lack of efficacy02
Withdrew: Withdrawal of consent01
Withdrew: Primary endpoint evaluation not complete01
Long Term Extension (LTE) Study
Participant flow — Long Term Extension (LTE) Study
MilestoneSubcutaneous (SC) Abatacept + Methotrexate (MTX) CohortSC Abatacept Cohort
Started090
Completed059
Not completed031
Withdrew: Lack of efficacy014
Withdrew: Adverse event09
Withdrew: Lost to follow-up03
Withdrew: Withdrawal by subject02
Withdrew: Other02
Withdrew: Poor/non-compliance01

Outcome measures

PrimaryNumber of Participants With Anti-abatacept or Anti-CTLA4-T Responses (Enzyme-linked Immunosorbent Assay [ELISA] Method) at Day 113 of the ST Study

ELISA is a validated, sensitive assay technique used to analyze presence of abatacept-specific antibodies in serum. For anti-abatacept antibody ELISA, a sample was considered seropositive if it had a titer of 400 or greater and if immunodepletion was observed. The responses that were negative in initial screen were reported as seronegative with a value of \< 400. A sample was considered positive in CTLA4-T antibody ELISA if it had a titer of 25 or greater and if immunodepletion was observed. The responses that were negative in initial screen were reported as seronegative with a value of \< 25.

Time frame:
Day 113
Reported as:
Number · participants
Number of Participants With Anti-abatacept or Anti-CTLA4-T Responses (Enzyme-linked Immunosorbent Assay [ELISA] Method) at Day 113 of the ST Study
participantsSubcutaneous (SC) Abatacept + Methotrexate (MTX) CohortSC Abatacept Monotherapy Cohort
Number of Participants With Anti-abatacept or Anti-CTLA4-T Responses (Enzyme-linked Immunosorbent Assay [ELISA] Method) at Day 113 of the ST Study00
SecondaryChange From Baseline in DAS28-CRP Score at End of 4-month (Day 113) of the ST Study

DAS28-CRP is a continuous variable which is a composite of 4 variables: the number of tender joint out of 28, the number of swollen joint out of 28, C-reactive protein (CRP) in milligrams/Liter (mg/L) and subject assessment of disease activity measure on a VAS of 100mm. DAS 28 = 0.56 \* sqrt(tender28) + 0.28 \* sqrt(swollen28) + 0.36 \* ln(CRP+1) + 0.014 \* VAS + 0.96.

Time frame:
Baseline and Month 4 (Day113).
Reported as:
Mean · Units on a scale
Change From Baseline in DAS28-CRP Score at End of 4-month (Day 113) of the ST Study
Units on a scaleSubcutaneous (SC) Abatacept + Methotrexate (MTX) CohortSC Abatacept Monotherapy Cohort
Change From Baseline in DAS28-CRP Score at End of 4-month (Day 113) of the ST Study-1.67 (-2.06 to -1.28)-1.94 (-2.46 to -1.42)
PrimaryNumber of Participants With Anti-abatacept or Anti-CTLA4-T Responses (ELISA Method) Over Time During the ST Study

ELISA is a validated, sensitive assay technique used to analyze presence of abatacept-specific antibodies in serum. For anti-abatacept antibody ELISA, a sample was considered seropositive if it had a titer of 400 or greater and if immunodepletion was observed. The responses that were negative in initial screen were reported as seronegative with a value of \< 400. A sample was considered positive in CTLA4-T antibody ELISA if it had a titer of 25 or greater and if immunodepletion was observed. The responses that were negative in initial screen were reported as seronegative with a value of \< 25.

Time frame:
Day 15, 29, 43, 57, 85,113 and 28, 56, and 85 days post last dose.
Reported as:
Number · participants
Number of Participants With Anti-abatacept or Anti-CTLA4-T Responses (ELISA Method) Over Time During the ST Study
participantsSubcutaneous (SC) Abatacept + Methotrexate (MTX) CohortSC Abatacept Monotherapy Cohort
Day 15, (n= 51,47)00
Day 29, (n= 50,48)20
Day 43, (n= 50,48)20
Day 57, (n= 50,47)11
Day 85, (n= 50,47)00
Day 113, (n= 50,45)00
Overall on Treatment visits, (n=51,49)21
28 Days last post dose, (n=2,3)00
56 Days last post dose, (n=2,3)00
85 Days last post dose, (n=4,4)01
Overall post visits, (n=4,4)01
Overall, (n=51,49)22
PrimaryNumber of Participants With Positive Anti-abatacept Responses to Abatacept (Meso-Scale Discovery [MSD] Electrochemiluminescence [ECL] Assay Method) Over Time During the ST Study

The ECL (MSD) assay method is a validated, sensitive assay technique used to analyze presence of abatacept-specific antibodies in serum. It is more sensitive and has a higher drug tolerance than ELISA method. For the anti-abatacept antibody ECL (MSD) assay, a sample was considered seropositive if it had a titer of 10 or greater and if immunodepletion was observed with abatacept, or abatacept and CTLA4-T. Those responses that were not positive in the initial screen or were not confirmed to be positive based on immunodepletion were reported as seronegative and were assigned a value of \< 10.

Time frame:
Day 15, 29, 43, 57, 85,113 and 28, 56 and 85 days post last dose.
Reported as:
Number · participants
Number of Participants With Positive Anti-abatacept Responses to Abatacept (Meso-Scale Discovery [MSD] Electrochemiluminescence [ECL] Assay Method) Over Time During the ST Study
participantsSubcutaneous (SC) Abatacept + Methotrexate (MTX) CohortSC Abatacept Monotherapy Cohort
Day 15, (n= 51,47)11
Day 29, (n= 50,48)10
Day 43, (n= 50,48)10
Day 57, (n= 50,47)10
Day 85, (n= 50,47)10
Day 113, (n=50,45)10
Overall on Treatment visits, (n=51,49)11
28 Days last post dose, (n=2,3)00
56 Days last post dose, (n=2,3)00
85 Days last post dose, (n=4,4)01
Overall post visits, (n=4,4)01
Overall, (n=51,49)12
PrimaryImmunogenicity in MTX Naive and MTX-previous Users in Cohort 1 at Day 113 of the ST Study (for ELISA Results)

ELISA is a validated, sensitive assay technique used to analyze presence of abatacept-specific antibodies in serum. For anti-abatacept antibody ELISA, a sample was considered seropositive if it had a titer of 400 or greater and if immunodepletion was observed. The responses that were negative in initial screen were reported as seronegative with a value of \< 400. A sample was considered positive in CTLA4-T antibody ELISA if it had a titer of 25 or greater and if immunodepletion was observed. The responses that were negative in initial screen were reported as seronegative with a value of \< 25.

Time frame:
Day 113.

No measurements were reported for this outcome.

PrimaryImmunogenicity in MTX Naive and MTX-previous Users in Cohort 1 at Day 113 of the ST Study (for MSD Results)

The ECL (MSD) assay method is a validated, sensitive assay technique used to analyze presence of abatacept-specific antibodies in serum. It is more sensitive and has a higher drug tolerance than the ELISA method. For anti-abatacept antibody ECL (MSD) assay, a sample was considered seropositive if it had a titer of 10 or greater and if immunodepletion was observed with abatacept, or abatacept and CTLA4-T. Those responses that were not positive in the initial screen or were not confirmed to be positive based on immunodepletion were reported as seronegative and were assigned a value of \< 10.

Time frame:
Day 113.

No measurements were reported for this outcome.

PrimaryCross Tabulations of the Number of Participants With Positive and Negative Immunogenicity Status at Baseline and Each Visit During the ST Study (for ELISA Results)

ELISA is a validated, sensitive assay technique used to analyze presence of abatacept-specific antibodies in serum. For anti-abatacept antibody ELISA, a sample was considered seropositive if it had a titer of 400 or greater and if immunodepletion was observed. The responses that were negative in initial screen were reported as seronegative with a value of \< 400. A sample was considered positive in CTLA4-T antibody ELISA if it had a titer of 25 or greater and if immunodepletion was observed. The responses that were negative in initial screen were reported as seronegative with a value of \< 25.

Time frame:
Baseline and on day 15, 29, 43, 57, 85 and 113

No measurements were reported for this outcome.

PrimaryCross Tabulations of the Number of Participants With Positive and Negative Immunogenicity Status at Baseline and Each Visit During the ST Study (for MSD Results)

The ECL (MSD) assay method is a validated, sensitive assay technique used to analyze presence of abatacept-specific antibodies in serum . It is more sensitive and has a higher drug tolerance than the ELISA method. For anti-abatacept antibody ECL(MSD) assay, a sample was considered seropositive if it had a titer of 10 or greater and if immunodepletion was observed with abatacept, or abatacept and CTLA4-T. Those responses that were not positive in the initial screen or were not confirmed to be positive based on immunodepletion were reported as seronegative and were assigned a value of \< 10.

Time frame:
Baseline and day 15, 29, 43, 57, 85 and 113.

No measurements were reported for this outcome.

SecondaryNumber of Participants With Clinically Meaningful Improvement at End of 4-month (Day 113) of the ST Study

A clinically meaningful improvement is defined as a greater than or equal to 1.2 reduction in DAS28-CRP score from baseline.

Time frame:
Day 113.
Reported as:
Number · participants
Number of Participants With Clinically Meaningful Improvement at End of 4-month (Day 113) of the ST Study
participantsSubcutaneous (SC) Abatacept + Methotrexate (MTX) CohortSC Abatacept Monotherapy Cohort
Number of Participants With Clinically Meaningful Improvement at End of 4-month (Day 113) of the ST Study3030
SecondaryChange From Baseline in Physical Functioning (HAQ-DI) at End of the 4-month Treatment Period (Day 113) of the ST Study

HAQ-DI takes into account participant's use of aids or devices or assistance in scoring algorithm for a disability category. The questionnaire includes 20 questions assessing physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The questions are evaluated on a 4-point scale: 0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty and 3 = unable to do. Higher scores indicate greater dysfunction. The score is calculated by summing worst scores in each domain and dividing by the number of domains answered.

Time frame:
Baseline and Month 4 (Day 113).
Reported as:
Mean · Units on a scale
Change From Baseline in Physical Functioning (HAQ-DI) at End of the 4-month Treatment Period (Day 113) of the ST Study
Units on a scaleSubcutaneous (SC) Abatacept + Methotrexate (MTX) CohortSC Abatacept Monotherapy Cohort
Change From Baseline in Physical Functioning (HAQ-DI) at End of the 4-month Treatment Period (Day 113) of the ST Study-0.31 (-0.43 to -0.19)-0.58 (-0.74 to -0.42)
SecondaryChange From Baseline in All HAQ-DI Components at End of the 4-month Treatment Period (Day 113) of the ST Study

HAQ-DI takes into account participant's use of aids or devices or assistance in scoring algorithm for a disability category. The questionnaire includes 20 questions assessing physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The questions are evaluated on a 4-point scale: 0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty and 3 = unable to do. Higher scores indicate greater dysfunction. The score is calculated by summing worst scores in each domain and dividing by the number of domains answered.

Time frame:
Baseline and Month 4 (Day113).
Reported as:
Mean · Units on a scale
Change From Baseline in All HAQ-DI Components at End of the 4-month Treatment Period (Day 113) of the ST Study
Units on a scaleSubcutaneous (SC) Abatacept + Methotrexate (MTX) CohortSC Abatacept Monotherapy Cohort
Dressing and Grooming, (n= 50,46)-0.44 (-0.63 to -0.25)-0.57 (-0.79 to -0.34)
Arising, (n= 50,46)-0.26 (-0.44 to -0.08)-0.59 (-0.81 to -0.36)
Eating, (n= 50,46)-0.28 (-0.50 to -0.06)-0.57 (-0.85 to -0.28)
Walking, (n= 50,46)-0.26 (-0.46 to -0.06)-0.54 (-0.75 to -0.34)
Hygiene, (n= 49,46)-0.33 (-0.55 to -0.10)-0.43 (-0.65 to -0.22)
Reaching, (n= 49,46)-0.24 (-0.47 to -0.02)-0.50 (-0.74 to -0.26)
Gripping, (n= 49,46)-0.31 (-0.54 to -0.07)-0.76 (-1.04 to -0.48)
Activities, (n= 49,46)-0.39 (-0.58 to -0.19)-0.67 (-0.90 to -0.45)
SecondaryCross Tabulations of Number of Participants With Positive and Negative Status for RF at Day 113 With Baseline, in the ST Study

RF is an autoantibody that is usually present in the serum of people with rheumatoid arthritis. The cut-point value for seroconversion was 15 IU/mL (\>= 15 IU/mL resulted in a positive result). Cross-tabulation of frequency of seroconversion of RF at Day 113 with baseline, in the ST period, was provided.

Time frame:
Baseline and Day 113.
Reported as:
Number · participants
Cross Tabulations of Number of Participants With Positive and Negative Status for RF at Day 113 With Baseline, in the ST Study
participantsSubcutaneous (SC) Abatacept + Methotrexate (MTX) CohortSC Abatacept Monotherapy Cohort
Negative at Baseline, negative at Day 1131215
Negative at Baseline, positive at Day 11320
Positive at Baseline, negative at Day 11311
Positive at Baseline, positive at Day 1133229
SecondaryNumber of Participants Who Died, Experienced SAEs, Experienced AEs or Who Discontinued Due to AEs During the ST Study

AEs: any new untoward medical occurrences/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose. Participants who discontinued the study due to any AEs or SAEs were recorded.

Time frame:
Continuously through ST period (upto Day 113). Includes the data from start of study drug therapy up to 56 days after the last dose (Day 113) or start of the long-term period whichever occurred first.
Reported as:
Number · participants
Number of Participants Who Died, Experienced SAEs, Experienced AEs or Who Discontinued Due to AEs During the ST Study
participantsSubcutaneous (SC) Abatacept + Methotrexate (MTX) CohortSC Abatacept Monotherapy Cohort
Deaths00
SAEs23
AEs3732
All SAEs Leading to Discontinuation11
All AEs Leading to Discontinuation31
SecondaryNumber of Participants Who Experienced Drug-related SAEs and Drug-related AEs During the ST Study

Drug-related AEs are those events with a relationship to the study therapy of certain; probable; possible; or missing. Drug-related SAEs are those events with any relationship to the study therapy.

Time frame:
Continuously through ST period (upto Day 113). Includes the data from start of study drug therapy up to 56 days after the last dose (Day 113) or start of the long-term period whichever occurred first.
Reported as:
Number · participants
Number of Participants Who Experienced Drug-related SAEs and Drug-related AEs During the ST Study
participantsSubcutaneous (SC) Abatacept + Methotrexate (MTX) CohortSC Abatacept Monotherapy Cohort
Drug-related AEs1412
Drug-related SAEs11
SecondaryNumber of Participants With AEs of Special Interest During the ST Study

An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition (even if not caused by the study drug). For this study, AEs of particular importance were associated with the use of immunomodulatory agents: infections, autoimmune disorders, malignancies, and injection reaction AEs (systemic AEs occurring within 24 hours of SC injection and local injection site reactions) were recorded.

Time frame:
Continuously through ST period (up to Day 113). Includes the data from start of study drug therapy up to 56 days after the last dose (Day 113) or start of the long-term period whichever occurred first.
Reported as:
Number · participants
Number of Participants With AEs of Special Interest During the ST Study
participantsSubcutaneous (SC) Abatacept + Methotrexate (MTX) CohortSC Abatacept Monotherapy Cohort
Infections1814
Malignant neoplasm00
Autoimmune disorders00
Local injection reactions34
Systemic injection reactions44
SecondaryNumber of Participants With Marked Abnormalities (MAs) in Hematology During the ST Study: Hemoglobin, Hematocrit, Platelet Count, Erythrocytes and Leukocytes

MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following hematology MA definitions specify the criteria for the data presented. Hemoglobin: \>3 g/dL decrease from pre-treatment (pre Rx); hematocrit: \<0.75 \* pre-Rx value; platelet count: \<0.67 \* (LLN -lower limit of normal) (or, if pre-Rx value \<LLN, then \<0.5 \* pre-Rx value and \<100,000/mm\^3); leukocytes: \<0.75 \* LLN or \>1.25 \* ULN (or, if pre-Rx value \<LLN, then \<0.8 \* pre-Rx or \>(ULN -upper limit of normal) ; erythrocytes: \<0.75 \* pre Rx.

Time frame:
Continuously from start of ST period up to 56 days post the last dose in the short-term period or start of the long-term period, whichever occurred first.
Reported as:
Number · participants
Number of Participants With Marked Abnormalities (MAs) in Hematology During the ST Study: Hemoglobin, Hematocrit, Platelet Count, Erythrocytes and Leukocytes
participantsSubcutaneous (SC) Abatacept + Methotrexate (MTX) CohortSC Abatacept Monotherapy Cohort
Low Hemoglobin00
Low Hematocrit00
Low Platelet Count00
High Platelet Count00
High Leukocytes12
Low Erythrocytes00
SecondaryNumber of Participants With MAs in Hematology During the ST Study: Neutrophils + Bands (Absolute), Lymphocytes (Absolute), Monocytes (Absolute), Basophils (Absolute) and Eosinophils (Absolute)

MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following hematology MA definitions specify the criteria for the data presented. Neutrophils + bands (absolute): \<1.00 \* 10\^3cells/microlitre (uL); lymphocytes (absolute): \<0.75 \* 10\^3 cells/uL or \>7.50 \* 10\^3 cells/uL; monocytes (absolute): \>2.00 \* 10\^3 cells/uL; basophils (absolute): \>0.40 \* 10\^3 cells/uL; eosinophils (absolute): \>0.75 \* 10\^3 cells/uL.

Time frame:
Continuously from start of ST period up to 56 days post the last dose in the short-term period or start of the long-term period, whichever occurred first.
Reported as:
Number · participants
Number of Participants With MAs in Hematology During the ST Study: Neutrophils + Bands (Absolute), Lymphocytes (Absolute), Monocytes (Absolute), Basophils (Absolute) and Eosinophils (Absolute)
participantsSubcutaneous (SC) Abatacept + Methotrexate (MTX) CohortSC Abatacept Monotherapy Cohort
Low Neutrophils + Bands (absolute)00
Low Lymphocytes (absolute)33
High Lymphocytes (absolute)00
High Monocytes (absolute)00
High Basophils (absolute)00
High Eosinophils (absolute)22
SecondaryNumber of Participants With MAs in Serum Chemistry During the ST Study: Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Bilirubin (Total), G-Glutamyl Transferase (G-GT) and Blood Urea Nitrogen (BUN)

MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following serum chemistry MA definitions specify MA criteria. ALP: \>2.0 \* ULN (if pre-Rx \> ULN, then \>3 \* pre-Rx); AST, ALT: \> 3 \* ULN (if pre-Rx \> ULN, then \> 4 \* pre-Rx); bilirubin (total): \>2 \* ULN, or if pre Rx \> ULN then \>4 \* Pre Rx; BUN : \>2 \* pre Rx; GGT : \>2 \* ULN, or if pre Rx \> ULN then \>3 \* pre Rx.

Time frame:
Continuously from start of ST period up to 56 days post the last dose in the short-term period or start of the long-term period, whichever occurred first.
Reported as:
Number · participants
Number of Participants With MAs in Serum Chemistry During the ST Study: Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Bilirubin (Total), G-Glutamyl Transferase (G-GT) and Blood Urea Nitrogen (BUN)
participantsSubcutaneous (SC) Abatacept + Methotrexate (MTX) CohortSC Abatacept Monotherapy Cohort
High ALP00
High AST10
High ALT10
High GGT02
High Bilirubin (total)00
High BUN11
SecondaryNumber of Participants With MAs in Serum Chemistry During the ST Study: Creatinine, Sodium (Serum), Potassium (Serum), Chloride (Serum), Calcium (Total) and Protein (Total)

MAs= laboratory measurements marked as abnormal: creatinine: \>1.5 \* pre-Rx; sodium (serum):\<0.95 \* LLN or \>1.05 \* ULN (if pre-Rx \< LLN, then \<0.95 \* pre-Rx or \>1.05 \* ULN. If pre-Rx \> ULN, then \>0.95 \* pre-Rx or \< ULN); potassium (serum):\<0.9 \* LLN or \>1.1 \* ULN (if pre-Rx \< LLN, then \<0.9 \* pre-Rx or \> ULN; chloride (serum),protein (total):\<0.9 \* LLN or \>1.1 8 ULN (if pre-Rx \< LLN, then \<0.9 \* pre-Rx or \> ULN. If pre-Rx \> ULN, then \>1.1 \* pre-Rx or \< LLN); calcium (total): \<0.8 \* LLN or \>1.2 \* ULN (if pre-Rx \< LLN, then \<0.9 \* pre-Rx or \> ULN. If pre-Rx \> ULN, then \>0.75 \* pre-Rx or \< ULN).

Time frame:
Continuously from start of ST period up to 56 days post the last dose in the short-term period or start of the long-term period, whichever occurred first.
Reported as:
Number · participants
Number of Participants With MAs in Serum Chemistry During the ST Study: Creatinine, Sodium (Serum), Potassium (Serum), Chloride (Serum), Calcium (Total) and Protein (Total)
participantsSubcutaneous (SC) Abatacept + Methotrexate (MTX) CohortSC Abatacept Monotherapy Cohort
High Chloride (serum)00
Low Chloride (serum)00
High Calcium (total)00
Low Calcium (total)00
High Protein (total)00
Low Protein (total)00
High Creatinine01
High Sodium (serum)00
Low Sodium (serum)00
Low Potassium (serum)10
High Potassium (serum)00
SecondaryNumber of Participants With MAs in Serum Chemistry During the ST Study: Glucose (Fasting Serum), Albumin, Glucose (Serum), Phosphorous (Inorganic) and Uric Acid

MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following serum chemistry MA definitions specify MA criteria. Glucose (fasting serum): \<0.8 \* LLN or \>1.5 ULN (if pre-Rx \<LLN, then \<2.0 \* pre-Rx or \>ULN; albumin: \<0.9 \* LLN (if pre-Rx \< LLN, then \<0.75 \* pre-Rx); uric acid: \>1.5 \* ULN (if pre-Rx \> ULN, then \>2.0 \* pre-Rx); phosphorous (inorganic):\<0.75 \* LLN or \>1.25 \* ULN (if pre-Rx \< ULN, then \<0.67 \* pre-Rx or \< ULN. If pre-Rx \> ULN, then \>1.33 \* re-Rx or \< LLN); glucose (serum): \<65 mg/dL or \>220 mg/dL.

Time frame:
Continuously from start of ST period up to 56 days post the last dose in the short-term period or start of the long-term period, whichever occurred first.
Reported as:
Number · participants
Number of Participants With MAs in Serum Chemistry During the ST Study: Glucose (Fasting Serum), Albumin, Glucose (Serum), Phosphorous (Inorganic) and Uric Acid
participantsSubcutaneous (SC) Abatacept + Methotrexate (MTX) CohortSC Abatacept Monotherapy Cohort
High Glucose (Fasting Serum) (n=8; n=21)00
Low Glucose (Fasting Serum) (n=8; n=21)00
Low Albumin (n=51; n=49)01
Low Glucose (Serum) (n=51; n=49)61
High Glucose(Serum) (n=51; n=49)21
High Uric Acid (n=51; n=49)00
High Phosphorous (inorganic) (n=51; n=49)00
Low Phosphorous (inorganic) (n=51; n=49)11
SecondaryNumber of Participants With MAs in Urinalysis During the ST Study: Protein, Glucose, Blood, Leukocyte Esterase, Red Blood Cells (RBC) and White Blood Cells (WBC)

MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following definitions specify the criteria for MAs in urinalysis: protein, glucose, blood, leukocyte esterase, RBC, WBC: \>= 2+ (or, if value \>= 4, or if pre-Rx value = 0 or 0.5, then \>= 2x or if pre-Rx value =1, then \>= 3, or if pre-Rx = 2 or 3, then \>= 4).

Time frame:
Continuously from start of ST period up to 56 days post the last dose in the short-term period or start of the long-term period, whichever occurred first.
Reported as:
Number · participants
Number of Participants With MAs in Urinalysis During the ST Study: Protein, Glucose, Blood, Leukocyte Esterase, Red Blood Cells (RBC) and White Blood Cells (WBC)
participantsSubcutaneous (SC) Abatacept + Methotrexate (MTX) CohortSC Abatacept Monotherapy Cohort
High Protein, urine (n= 51,49)02
High Glucose, urine (n= 51,49)10
High Blood, urine (n= 51,49)13
High Leukocyte Esterase, urine (n= 18,17)23
High WBC, urine (n= 15,19)36
High RBC, urine (n= 12,17)17
SecondaryNumber of Participants With Anti-nuclear Antibody (ANA) Category at Day 113 of the ST Study

ANA status was categorized as negative or positive corresponding to the following dilutions: less than 1:160 and greater than equal to 1:160.

Time frame:
Day 113.
Reported as:
Number · participants
Number of Participants With Anti-nuclear Antibody (ANA) Category at Day 113 of the ST Study
participantsSubcutaneous (SC) Abatacept + Methotrexate (MTX) CohortSC Abatacept Monotherapy Cohort
Negative3632
Positive1112
SecondaryNumber of Participants With Anti-double Stranded DNA (dsDNA) Category at Day 113 of the ST Study

Anti-dsDNA antibody status was categorized as negative or positive based upon assay-specific numeric cut-off values.

Time frame:
Day 113.
Reported as:
Number · participants
Number of Participants With Anti-double Stranded DNA (dsDNA) Category at Day 113 of the ST Study
participantsSubcutaneous (SC) Abatacept + Methotrexate (MTX) CohortSC Abatacept Monotherapy Cohort
Negative4137
Positive48
SecondaryNumber of Participants With Clinically Meaningful Vital Signs During the ST Study

Vital signs measurements (including seated blood pressure, heart rate and temperature) were recorded. The investigator used his/her clinical judgment to decide whether or not abnormalities in vital signs/physical examination were clinically meaningful.

Time frame:
At screening and on days 1,15,29,43, 57, 85 and 113.
Reported as:
Number · participants
Number of Participants With Clinically Meaningful Vital Signs During the ST Study
participantsSubcutaneous (SC) Abatacept + Methotrexate (MTX) CohortSC Abatacept Monotherapy Cohort
Number of Participants With Clinically Meaningful Vital Signs During the ST Study00
SecondaryMinimum Plasma Concentration (Cmin) at Each Visit During the 4 Month Treatment Period of the ST Study

Cmin serum abatacept concentration was obtained directly from the concentration-time data.

Time frame:
Days 1, 15, 29, 43, 57, 85 and 113.
Reported as:
Geometric mean · microgram/mL
Minimum Plasma Concentration (Cmin) at Each Visit During the 4 Month Treatment Period of the ST Study
microgram/mLSubcutaneous (SC) Abatacept + Methotrexate (MTX) CohortSC Abatacept Monotherapy Cohort
Day 15, (n= 40,41)13.69 (4.80 to 27.40)11.23 (2.70 to 27.10)
Day 29, (n= 49,45)19.39 (6.10 to 41.80)15.64 (4.40 to 42.20)
Day 43, (n= 41,38)23.40 (10.80 to 44.40)18.06 (5.20 to 48.10)
Day 57, (n= 48,38)24.38 (10.90 to 41.10)21.71 (9.60 to 68.00)
Day 85, (n= 47,39)28.77 (11.30 to 69.20)20.38 (2.60 to 50.00)
Day 113, (n=46,37)28.46 (10.10 to 66.50)23.74 (6.60 to 70.80)
SecondaryNumber of Participants With Abatacept Induced Antibody Responses Over Time During the LTE Study (ECL Method) - All Treated Participants in LTE Study

The Meso-Scale Discovery (MSD) electrochemiluminescence (ECL) assay method is a validated, sensitive assay technique used to analyze presence of abatacept-specific antibodies in serum. It is more sensitive and has a higher drug tolerance than ELISA method. For the anti-abatacept antibody ECL (MSD) assay, a sample was considered seropositive if it had a titer of 10 or greater and if immunodepletion was observed with abatacept, or abatacept and CTLA4-T. Those responses that were not positive in the initial screen or were not confirmed to be positive based on immunodepletion were reported as seronegative and were assigned a value of \< 10. Antibody responses included CTLA4 and possibly immune globulin (IG), IG and/or junction region.

Time frame:
Days 197, 281, 365, 449, 533, 617, 729, 813, 897, 981, 1093, 1177, 1261, 1345, 1457, 1541, 1625, 1709, 1821, 1989, days post dose: 28, 56, 85, 168
Reported as:
Number · participants
Number of Participants With Abatacept Induced Antibody Responses Over Time During the LTE Study (ECL Method) - All Treated Participants in LTE Study
participantsAbatacept Long Term Extension (LTE) Study
Days 197, 281, 365, 449 (n=86, 87, 85, 79)0
Day 533 (n=76)1
Days 617, 729, 813 (n=74, 70, 66)0
Days 897, 981 (n=66, 58)0
Day 1093 (n=65)2
Day 1177 (n=8)0
Day 1261 (n=57)1
Day 1345 (n=24)0
Day 1457 (n=59)3
Day 1541 (n=24)1
Day 1625 (n=18)2
Days 1709, 1821 (n=2, 11)0
Day 1989 (n=13)1
Overall on Treatment (n=88)11
28 days post last dose (n=18)0
56 days post last dose (n=15)2
85 days post last dose (n=16)2
168 days post last dose (n=3)2
Overall post last dose visits (n=23)4
Overall (n=90)13
SecondaryChange From Baseline in DAS28-CRP Score in the LTE Study - All Treated Participants in LTE Study

DAS28-CRP is a continuous variable which is a composite of 4 variables: the number of tender joints out of 28, the number of swollen joints out of 28, C-reactive protein (CRP) in milligrams/Liter (mg/L) and subject assessment of disease activity measure on a VAS of 100mm. DAS 28 = 0.56 \* sqrt(tender28) + 0.28 \* sqrt(swollen28) + 0.36 \* ln(CRP+1) + 0.014 \* VAS + 0.96. Baseline was Day 1 of the ST Study; Day 113 was the end of the ST Study.

Time frame:
Baseline, Day 113, Day 1345
Reported as:
Mean · Units on a scale
Change From Baseline in DAS28-CRP Score in the LTE Study - All Treated Participants in LTE Study
Units on a scaleAbatacept Long Term Extension Study
Day 113 (n=88)-1.89 (-2.2 to -1.5)
Day 1345 (n=61)-2.39 (-2.8 to -1.9)
SecondaryNumber of Participants With Clinically Meaningful Improvement From Baseline in the LTE Study - All Treated Participants in LTE Study

A clinically meaningful improvement is defined as a greater than or equal to 1.2 reduction in DAS28-CRP score from baseline. Baseline was Day 1 of the ST Study. Day 113 was the end of the ST Study.

Time frame:
Baseline, Day 113, Day 1345
Reported as:
Number · participants
Number of Participants With Clinically Meaningful Improvement From Baseline in the LTE Study - All Treated Participants in LTE Study
participantsAbatacept Long Term Extension Study
Day 113 (n=88)59
Day 1345 (n=61)43
SecondaryNumber of Participants in DAS28-CRP Remission and Number of Participants With Low Disease Activity (LDA) in the LTE Study - All Treated Participants in the LTE

DAS28-CRP remission was defined as DAS28-CRP less than 2.6 and LDA was defined as DAS28-CRP less than, equal to 3.2. End of ST Study was Day 113.

Time frame:
Day 113, Day 1345
Reported as:
Number · participants
Number of Participants in DAS28-CRP Remission and Number of Participants With Low Disease Activity (LDA) in the LTE Study - All Treated Participants in the LTE
participantsAbatacept Long Term Extension Study
Remission at Day 113 (n=90)28
Remission at Day 1345 (n=63)28
LDA at Day 113 (n=90)45
LDA at Day 1345 (n=63)37
SecondaryChange From Baseline in HAQ-DI in the LTE Study - All Treated Participants in LTE Study

HAQ-DI takes into account participant's use of aids or devices or assistance in scoring algorithm for a disability category. The questionnaire includes 20 questions assessing physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The questions are evaluated on a 4-point scale: 0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty and 3 = unable to do. Higher scores indicate greater dysfunction. The score is calculated by summing worst scores in each domain and dividing by the number of domains answered. Baseline was Day 1 in the ST Study and Day 113 was the last day of the ST Study.

Time frame:
Baseline, Day 113, Day 1345
Reported as:
Mean · units on a scale
Change From Baseline in HAQ-DI in the LTE Study - All Treated Participants in LTE Study
units on a scaleAbatacept Long Term Extension Study
HAQ-DI at Day 113 (n=89)-0.47 (-0.57 to -0.36)
HAQ-DI at Day 1345 (n=64)-0.56 (-0.71 to -0.42)
SecondaryNumber of Participants With HAQ Responses in the LTE Study - All Treated Participants in the LTE STudy

HAQ response was defined as an improvement of at least 0.3 units from baseline in the HAQ Disability Index (HAQ DI). Baseline was Day 1 of the ST Study and Day 113 was the last day of the ST Study.

Time frame:
Baseline, Day 113, Day 1345
Reported as:
Number · participants
Number of Participants With HAQ Responses in the LTE Study - All Treated Participants in the LTE STudy
participantsAbatacept Long Term Extension Study
HAQ DI Response at Day 113 (n=89)53
HAQ DI Response at Day 1345 (n=64)41
SecondaryNumber of Participants With Negative Status for RF up to 7 Days After Last Dose of Abatacept in the LTE Period - All Treated Participants in LTE Study

RF is an autoantibody that is usually present in the serum of people with rheumatoid arthritis. The cut-point value for seroconversion was 15 IU/mL (\>= 15 IU/mL resulted in a positive result).

Time frame:
Continuously from start of LTE period up to 7 days post the last dose
Reported as:
Number · participants
Number of Participants With Negative Status for RF up to 7 Days After Last Dose of Abatacept in the LTE Period - All Treated Participants in LTE Study
participantsAbatacept Long Term Extension Study
Number of Participants With Negative Status for RF up to 7 Days After Last Dose of Abatacept in the LTE Period - All Treated Participants in LTE Study20
SecondaryChange From Baseline in DAS28-CRP Score and Physical Function (HAQ-DI) Score in the LTE Study - Abatacept Monotherapy Subgroup

Abatacept Monotherapy Subgroup consisted of participants who received SC abatacept and did not receive MTX in the ST and LTE Studies. DAS28-CRP: continuous variable which is a composite of 4 variables:number of tender joints out of 28, number of swollen joints out of 28, C-reactive protein (CRP) in mg/L and self assessment of disease activity measure on a VAS of 100mm. DAS 28 = 0.56 \* sqrt(tender28) + 0.28 \* sqrt(swollen28) + 0.36 \* ln(CRP+1) + 0.014 \* VAS + 0.96. HAQ-DI includes 20 questions assessing physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities on a 4-point scale: 0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty and 3 = unable to do. Higher scores indicate greater dysfunction. The score sums worst scores in each domain and divides by the number of domains answered. Baseline was Day 1 of Short Term Study. Day 113 was the last day of the Short Term Study.

Time frame:
Baseline, Day 113, Day 1345
Reported as:
Mean · units on a scale
Change From Baseline in DAS28-CRP Score and Physical Function (HAQ-DI) Score in the LTE Study - Abatacept Monotherapy Subgroup
units on a scaleAbatacept Monotherapy Subgroup
DAS-CRP at Day 113 (n=31)-2.42 ± 0.29
DAS-CRP at Day 1345 (n=23)-2.58 ± 0.30
HAQ-DI at Day 113 (n=32)-0.60 ± 0.10
HAQ-DI at Day 1345 (n=25)-0.65 ± 0.12
SecondaryNumber of Participants in DAS 28-CRP Remission and Low Disease Activity (LDA) in the LTE Study - Abatacept Monotherapy Subgroup

Remission was defined as DAS 28-CRP \< 2.6 and LDA was defined as DAS 28-CRP \<= 3.2. End of ST Study was Day 113. Abatacept Monotherapy Subgroup was defined as those participants who received as at least 1 dose of abatacept and did not receive MTX in the ST and LTE Studies.

Time frame:
Day 113, Day 1345
Reported as:
Number · participants
Number of Participants in DAS 28-CRP Remission and Low Disease Activity (LDA) in the LTE Study - Abatacept Monotherapy Subgroup
participantsAbatacept Monotherapy Subgroup
Remission at Day 113 (n=32)14
Remission at Day 1345 (n=24)9
LDA at Day 113 (n=32)18
LDA at Day 1345 (n=24)13
SecondaryNumber of Participants Who Died, Experienced Serious Adverse Events (SAEs), Adverse Events (AEs), or Discontinued Due to AEs and/or SAEs During the LTE Period - All Treated Participants in LTE Study

AEs: any new untoward medical occurrences/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose. Drug-related AEs/SAEs are those events with a relationship to the study therapy of certain; probable; possible; or missing.

Time frame:
Continuously from start of LTE Study up to 56 days post the last dose
Reported as:
Number · participants
Number of Participants Who Died, Experienced Serious Adverse Events (SAEs), Adverse Events (AEs), or Discontinued Due to AEs and/or SAEs During the LTE Period - All Treated Participants in LTE Study
participantsAbatacept Long Term Extension Study
Deaths0
SAEs34
Related SAEs6
Discontinued due to SAEs3
AEs86
Related AEs34
Discontinued due to AEs8
SecondaryNumber of Participants With AEs of Special Interest During the LTE Study - All Treated Participants in LTE Study

An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition (even if not caused by the study drug). For this study, AEs of particular importance were associated with the use of immunomodulatory agents: infections, autoimmune disorders, malignancies, and injection reaction AEs (systemic AEs occurring within 24 hours of SC injection and local injection site reactions) were recorded.

Time frame:
Continuously from start of LTE Study up to 56 days post the last dose
Reported as:
Number · participants
Number of Participants With AEs of Special Interest During the LTE Study - All Treated Participants in LTE Study
participantsAbatacept Long Term Extension Study
Infections69
Autoimmune Disorders5
Malignancies4
Local Injection Site Reactions2
Systemic Injection Reaction12
SecondaryNumber of Participants With Marked Abnormalities (MAs) in Hematology During the LTE Period - All Treated Participants in LTE Study

MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following hematology MA definitions specify the criteria for the data presented. Hemoglobin: \>3 g/dL decrease from pre-treatment (pre Rx); hematocrit: \<0.75 \* pre-Rx value; platelet count: \<0.67 \* (LLN -lower limit of normal) (or, if pre-Rx value \<LLN, then \<0.5 \* pre-Rx value and \<100,000/mm\^3); leukocytes: \<0.75 \* LLN or \>1.25 \* ULN (or, if pre-Rx value \<LLN, then \<0.8 \* pre-Rx or \>(ULN -upper limit of normal) ; erythrocytes: \<0.75 \* pre Rx. Neutrophils + bands (absolute): \<1.00 \* 10\^3cells/microlitre (uL); lymphocytes (absolute): \<0.75 \* 10\^3 cells/uL or \>7.50 \* 10\^3 cells/uL; monocytes (absolute): \>2.00 \* 10\^3 cells/uL; basophils (absolute): \>0.40 \* 10\^3 cells/uL; eosinophils (absolute): \>0.75 \* 10\^3 cells/uL.

Time frame:
Continuously from start of LTE Study up to 56 days post the last dose
Reported as:
Number · participants
Number of Participants With Marked Abnormalities (MAs) in Hematology During the LTE Period - All Treated Participants in LTE Study
participantsAbatacept Long Term Extension Study
Low Hemoglobin (n=90)1
Low Hematocrit (n=90)0
Low Erythrocytes (n=90)0
Low Platelet Count (n=89)0
High Platelet Count (n=89)0
Low Leukocytes (n=90)2
High Leukocytes (n=90)5
Low Neutrophils + bands0
Low Lymphocytes (n=90)6
High Lymphocytes (n=90)1
High Monocytes (n=90)2
High Basophils (n=90)0
High Eosinophils (n=90)13
SecondaryNumber of Participants With MAs in Serum Chemistry (Liver and Kidney Function) During the LTE Period - All Treated Participants in LTE Study

MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Bilirubin (Total), G-Glutamyl Transferase (G-GT), Blood Urea Nitrogen (BUN) and Creatinine MA criteria: ALP: \>2.0 \* ULN (if pre-Rx \> ULN, then \>3 \* pre-Rx); AST, ALT: \> 3 \* ULN (if pre-Rx \> ULN, then \> 4 \* pre-Rx); bilirubin (total): \>2 \* ULN, or if pre Rx \> ULN then \>4 \* Pre Rx; BUN : \>2 \* pre Rx; GGT : \>2 \* ULN, or if pre Rx \> ULN then \>3 \* pre Rx; creatinine: \>1.5 \* pre-Rx.

Time frame:
Continuously from start of LTE Study up to 56 days post the last dose
Reported as:
Number · participants
Number of Participants With MAs in Serum Chemistry (Liver and Kidney Function) During the LTE Period - All Treated Participants in LTE Study
participantsAbatacept Long Term Extension Study
High ALP (n=90)0
High AST (n=90)1
High ALT (n=90)3
High G-GT (n=90)2
High Bilirubin (n=90)0
High BUN (n=90)6
High Creatinine (n=90)7
SecondaryNumber of Participants With MAs in Serum Chemistry (Electrolytes, Glucose, Protein, and Metabolite) During the LTE Period - All Treated Participants in LTE Study

Sodium (serum):\<0.95 \* LLN or \>1.05 \* ULN (if pre-Rx \< LLN, then \<0.95 \* pre-Rx or \>1.05 \* ULN. If pre-Rx \> ULN, then \>0.95 \* pre-Rx or \< ULN); potassium (serum):\<0.9 \* LLN or \>1.1 \* ULN (if pre-Rx \< LLN, then \<0.9 \* pre-Rx or \> ULN; chloride (serum),protein (total):\<0.9 \* LLN or \>1.1 8 ULN (if pre-Rx \< LLN, then \<0.9 \* pre-Rx or \> ULN. If pre-Rx \> ULN, then \>1.1 \* pre-Rx or \< LLN); calcium (total): \<0.8 \* LLN or \>1.2 \* ULN (if pre-Rx \< LLN, then \<0.9 \* pre-Rx or \> ULN. If pre-Rx \> ULN, then \>0.75 \* pre-Rx or \< ULN); phosphorous (inorganic):\<0.75 \* LLN or \>1.25 \* ULN (if pre-Rx \< ULN, then \<0.67 \* pre-Rx or \< ULN. If pre-Rx \> ULN, then \>1.33 \* re-Rx or \<LLN); glucose (serum): \<65 mg/dL or \>220 mg/dL; Glucose (fasting serum): \<0.8 \* LLN or \>1.5 ULN (if pre-Rx \<LLN, then \<2.0 \* pre-Rx or \>ULN; albumin: \<0.9 \* LLN (if pre-Rx \< LLN, then \<0.75 \* pre-Rx); uric acid: \>1.5 \* ULN (if pre-Rx \> ULN, then \>2.0 \* pre-Rx).

Time frame:
Continuously from start of LTE Study up to 56 days post the last dose
Reported as:
Number · participants
Number of Participants With MAs in Serum Chemistry (Electrolytes, Glucose, Protein, and Metabolite) During the LTE Period - All Treated Participants in LTE Study
participantsAbatacept Long Term Extension Study
High and/or Low Sodium (n=90)0
Low Potassium (n=90)2
High Potassium (n=90)0
High and/or Low Chloride0
High and/or Low Total Calcium (n=90)0
High and/or Low Inorganic Phosphorus (n=90)0
Low Glucose (n=90)21
High Glucose (n=90)1
Low Fasting Glucose (n=28)3
High Fasting Glucose (n=28)1
High and/or Low Total Protein (n=90)0
Low Albumin (n=90)0
High Uric Acid (n=90)1
SecondaryNumber of Participants With MAs in Urinalysis During the LTE Period: Protein, Glucose, Blood, Leukocyte Esterase, Red Blood Cells (RBC) and White Blood Cells (WBC) - All Treated Participants in LTE Study

MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following definitions specify the criteria for MAs in urinalysis: protein, glucose, blood, leukocyte esterase, RBC, WBC: \>= 2+ (or, if value \>= 4, or if pre-Rx value = 0 or 0.5, then \>= 2x or if pre-Rx value =1, then \>= 3, or if pre-Rx = 2 or 3, then \>= 4).

Time frame:
Continuously from start of LTE Study up to 56 days post the last dose
Reported as:
Number · participants
Number of Participants With MAs in Urinalysis During the LTE Period: Protein, Glucose, Blood, Leukocyte Esterase, Red Blood Cells (RBC) and White Blood Cells (WBC) - All Treated Participants in LTE Study
participantsAbatacept Long Term Extension Study
High Urine Protein (n=89)6
High Urine Glucose (n=89)2
High Urine Blood (n=89)13
High Urine Esterase (n=45)12
High Urine WBC (n=51)26
High Urine RBC (n=47)16

Adverse events

Collected over Short Term (ST) Study: Day 1 up to Day 113. LTE Study: Start of LTE Study up to 56 days post the last dose. Study initiated 2007 and completed LTE 2014.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Short Term Study: Subcutaneous (SC) Abatacept + Methotrexate—2/51 (3.9%)16/51 (31.4%)
Short Term Study: SC Abatacept Monotherapy—3/49 (6.1%)13/49 (26.5%)
Long Term Extension (LTE):125 mg SC Abatacept—34/90 (37.8%)70/90 (77.8%)
Most frequent serious events
Showing 10 of 51
Most frequent serious events
EventShort Term Study: Subcutaneous (SC) Abatacept + MethotrexateShort Term Study: SC Abatacept MonotherapyLong Term Extension (LTE):125 mg SC Abatacept
OsteoarthritisMusculoskeletal and connective tissue disorders0/510/493/90
Chest painGeneral disorders0/510/492/90
CholelithiasisHepatobiliary disorders0/510/492/90
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/510/492/90
Atrial fibrillationCardiac disorders0/510/492/90
PneumoniaInfections and infestations0/511/491/90
Lower Respiratory Tract InfectionInfections and infestations0/511/490/90
Cartilage InjuryInjury, poisoning and procedural complications0/511/490/90
Pneumocystis Jiroveci PneumoniaInfections and infestations1/510/490/90
SyncopeNervous system disorders1/510/490/90
Most frequent other events
Showing 10 of 27
Most frequent other events
EventShort Term Study: Subcutaneous (SC) Abatacept + MethotrexateShort Term Study: SC Abatacept MonotherapyLong Term Extension (LTE):125 mg SC Abatacept
SinusitisInfections and infestations0/510/4922/90
Upper respiratory tract infectionInfections and infestations6/512/4921/90
Urinary tract infectionInfections and infestations1/513/4917/90
BronchitisInfections and infestations0/510/4912/90
NasopharyngitisInfections and infestations0/510/4912/90
HeadacheNervous system disorders5/513/495/90
ContusionInjury, poisoning and procedural complications0/510/498/90
HypertensionVascular disorders0/510/498/90
FallInjury, poisoning and procedural complications0/510/498/90
VomitingGastrointestinal disorders0/514/490/90

Baseline characteristics

Age, Continuous
Age, Continuous(years)Subcutaneous (SC) Abatacept + Methotrexate (MTX) CohortSC Abatacept Monotherapy CohortTotal
Median55.0 ± 11.554.0 ± 10.254.0 ± 10.9
Sex: Female, Male
Sex: Female, Male(Participants)Subcutaneous (SC) Abatacept + Methotrexate (MTX) CohortSC Abatacept Monotherapy CohortTotal
Female344175
Male17825
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Subcutaneous (SC) Abatacept + Methotrexate (MTX) CohortSC Abatacept Monotherapy CohortTotal
White423476
Black7411
American Indian/Alaska Native101
Asian11011
Other races011
Weight continuous
Weight continuous(kilogram (Kg))Subcutaneous (SC) Abatacept + Methotrexate (MTX) CohortSC Abatacept Monotherapy CohortTotal
Mean84.6 ± 18.881.6 ± 22.483.1 ± 20.6
Weight customized
Weight customized(participants)Subcutaneous (SC) Abatacept + Methotrexate (MTX) CohortSC Abatacept Monotherapy CohortTotal
< 60 Kg4812
60 - 100 Kg363167
> 100 Kg111021
Disease activity score C-reactive protein (DAS 28-CRP)
Disease activity score C-reactive protein (DAS 28-CRP)(Units on a scale)Subcutaneous (SC) Abatacept + Methotrexate (MTX) CohortSC Abatacept Monotherapy CohortTotal
Mean5.1 ± 1.25.8 ± 1.55.4 ± 1.4
Tender joints
Tender joints(tender joints)Subcutaneous (SC) Abatacept + Methotrexate (MTX) CohortSC Abatacept Monotherapy CohortTotal
Mean23.9 ± 18.024.3 ± 14.224.1 ± 16.2
Swollen joints
Swollen joints(swollen joints)Subcutaneous (SC) Abatacept + Methotrexate (MTX) CohortSC Abatacept Monotherapy CohortTotal
Mean16.2 ± 12.018.3 ± 12.217.2 ± 12.1

5 further baseline measures are reported on the registry.

08

Study locations

22 sites
  • Rheumatology Associates Of North Alabama
    Huntsville, Alabama 35801, United States
  • Coastal Clinical Research Inc
    Mobile, Alabama 36608, United States
  • Stanford University School Of Medicine
    Palo Alto, California 94304, United States
  • Boulder Medical Center
    Boulder, Colorado 80304, United States
  • The Arthritis Center
    Palm Harbor, Florida 34684, United States
  • Medical Towers South
    Louisville, Kentucky 40298, United States
  • Westroads Medical Group
    Omaha, Nebraska 68114, United States
  • Regional Rheumatology Associates
    Binghamton, New York 13905, United States
  • Physicians East, Pa
    Greenville, North Carolina 27834, United States
  • Healthcare Research Consultants
    Tulsa, Oklahoma 74135, United States
  • East Penn Rheumatology Associates
    Bethlehem, Pennsylvania 18015, United States
  • Altoona Center For Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • Low Country Rheumatology, Pa
    Charleston, South Carolina 29406, United States
  • Columbia Arthritis Center
    Columbia, South Carolina 29204, United States
  • Rheumatic Disease Center
    Glendale, Wisconsin 53217, United States
  • Local Institution
    Maroochydore, Queensland 4558, Australia
  • Local Institution
    Hobart, Tasmania 7001, Australia
  • Local Institution
    Malvern, Victoria 3144, Australia
  • Local Institution
    D.f., Distrito Federal 06700, Mexico
  • Local Institution
    Guadalajara, Jalisco 44100, Mexico
  • Local Institution
    Berea, Kwa Zulu Natal 4001, South Africa
  • Local Institution
    Panorama, Western Cape 7500, South Africa
09

References and documents

Publications

  • Nash P, Nayiager S, Genovese MC, Kivitz AJ, Oelke K, Ludivico C, Palmer W, Rodriguez C, Delaet I, Elegbe A, Corbo M. Immunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label study. Arthritis Care Res (Hoboken). 2013 May;65(5):718-28. doi: 10.1002/acr.21876. PubMed 23097311 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2007, a primary completion of Dec 2008 and a completion of Feb 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2011, 2 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2007
First posted
Oct 22, 2007
Start
Dec 2007
Primary completionActual
Dec 2008
CompletionActual
Feb 2014
Results first posted
Jan 24, 2011
Last update
Mar 23, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00547521
Responsible party
Sponsor
First posted
Oct 22, 2007
Start date
Dec 2007
Primary completion
Dec 2008
Completion
Feb 2014
Results posted
Jan 24, 2011
Last update
Mar 23, 2015

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abatacept

Start the discussion